Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma

Lindsay R Hammons; Aniko Szabo; Abhishek Janardan; Binod Dhakal; Saurabh Chhabra; Anita D'Souza; Meera Mohan

doi:10.1001/jamanetworkopen.2022.38961

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma

JAMA Netw Open. 2022 Oct 3;5(10):e2238961. doi: 10.1001/jamanetworkopen.2022.38961.

Authors

Lindsay R Hammons¹, Aniko Szabo¹, Abhishek Janardan¹, Binod Dhakal¹, Saurabh Chhabra¹, Anita D'Souza¹, Meera Mohan¹

Affiliation

¹ Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee.

No abstract available

Plain language summary

This case series describes the kinetics of humoral deficiency in patients with relapsed refractory multiple myeloma treated with bispecific antibodies, the infectious complications, and response to COVID-19 immunization.

MeSH terms

Antibodies, Bispecific* / therapeutic use
Antibodies, Monoclonal, Humanized
Humans
Kinetics
Multiple Myeloma* / drug therapy
Neoplasm Recurrence, Local

Substances

Antibodies, Bispecific
Antibodies, Monoclonal, Humanized